How Does Trastuzumab Work to Fight HER2-Positive Cancer

Trastuzumab is a lab-made antibody that locks onto the HER2 protein sitting on the surface of cancer cells, blocking the growth signals HER2 sends and flagging those cells for destruction by the immune system. About one in five breast cancers overproduces HER2, and trastuzumab transformed this aggressive subtype from one of the worst prognoses in breast cancer into one of the most treatable. But the drug does not work through a single trick; it fights cancer through at least four distinct mechanisms, and understanding those mechanisms helps explain why it is combined with other drugs, why it sometimes fails, and why it cannot reach every tumor in the body.

How Trastuzumab Attaches to the HER2 Protein

HER2 is a receptor that sits on the outer surface of cells. In healthy tissue, it participates in normal cell growth and repair. In HER2-positive cancers, the gene for HER2 is amplified, meaning the cell churns out far too many copies of the receptor. All those extra receptors constantly fire growth signals into the cell, telling it to divide without the usual restraints.

Trastuzumab binds to a specific region of the HER2 receptor’s outer portion known as domain IV.¹ That binding spot is not the same surface HER2 uses to pair up with other receptors, so trastuzumab does not directly block HER2 from forming receptor pairs the way a cork plugs a bottle. Instead, it interferes with the receptor’s ability to function properly once it has paired up, disrupting the downstream growth signals rather than simply preventing the physical pairing.

One consequence of trastuzumab binding is that it prevents a process called shedding. Normally, enzymes called metalloproteinases can clip the outer portion of HER2 off the cell surface, releasing a fragment that floats free in the bloodstream. The leftover stump on the cell is actually more active than the intact receptor, so shedding makes the cancer more aggressive. Trastuzumab blocks this clipping, keeping HER2 in its full-length, less-dangerous form.² That matters clinically because shed HER2 fragments can also be detected in blood tests, and high levels of them have been linked to worse outcomes.

Recruiting the Immune System

Trastuzumab is not just a molecular plug. Because it is an antibody, it has a tail region that immune cells can recognize, and this turns HER2-positive cancer cells into targets. Two main immune processes are involved, and they are carried out by different immune cells.

Natural killer cells, a type of white blood cell, recognize trastuzumab sitting on a cancer cell and kill the cell directly in a process called antibody-dependent cell-mediated cytotoxicity. Meanwhile, monocytes, another immune cell type, grab trastuzumab-coated cancer cells and engulf them whole through phagocytosis. Research has shown that these two cell types have complementary roles: natural killer cells are effective at direct killing but not at phagocytosis, while monocytes are effective at engulfing tumor cells but less so at outright killing them.³ The immune recruitment arm of trastuzumab’s action is considered one of its most important effects, and researchers have found that patients whose immune cells respond more vigorously to trastuzumab-coated targets tend to do better on the drug.

Slowing Cell Division and Starving the Tumor

Beyond its immune-recruiting role, trastuzumab directly interferes with the cancer cell’s ability to multiply. When trastuzumab is present, cells get stuck in the resting phase of the cell cycle and cannot proceed to division. This arrest is driven by an increase in a protein called p27, which acts as a brake on cell-cycle progression. The effect is concentration-dependent and, once established, long-lasting and irreversible even if the drug is removed.⁴ Trastuzumab also sharply reduces the activity of CDK2, an enzyme that normally pushes cells into DNA replication, while leaving other cell-cycle enzymes like CDK4 untouched.⁵

Trastuzumab also affects the tumor’s blood supply. Tumors need new blood vessels to grow past a small size, and HER2 signaling promotes the production of VEGF, a protein that stimulates blood-vessel formation. Trastuzumab has been shown to reduce VEGF expression in HER2-overexpressing tumor cells, dampening the signal that recruits new blood vessels.⁶ A tumor that cannot build its own blood supply grows more slowly and is more vulnerable to other treatments.

Why Trastuzumab Is Almost Always Paired With Other Drugs

Trastuzumab is rarely given alone. In both breast cancer and other HER2-positive cancers, it is combined with chemotherapy drugs, and there are good mechanistic reasons for this beyond the general principle that two treatments are better than one.

HER2 overexpression makes cancer cells more resistant to certain chemotherapy drugs, particularly taxanes like paclitaxel, by activating anti-death survival pathways inside the cell. Trastuzumab reverses this protection, effectively re-sensitizing the cancer to paclitaxel.⁷ Laboratory studies confirmed additive interactions between trastuzumab and several common chemotherapy agents, including doxorubicin, epirubicin, and paclitaxel, across multiple HER2-positive cell lines.⁸

The anti-blood-vessel effect also benefits from combination therapy. When trastuzumab is paired with paclitaxel, the two drugs together suppress tumor blood-vessel formation more effectively than either one on its own, partly because the combination more strongly inhibits the Akt signaling pathway, which sits at a crossroads of cell survival and blood-vessel growth.⁹

Dual Targeting With Pertuzumab

A common question patients encounter is why they might receive two HER2-targeting antibodies at once. Pertuzumab is another antibody aimed at HER2, but it binds a different region of the receptor than trastuzumab does. Pertuzumab directly blocks HER2 from pairing with other receptors, especially HER3, while trastuzumab works through the domain IV mechanisms already described. When used together, the two antibodies are more effective than either alone: the combination has been shown to synergistically inhibit HER2-positive cancer cell survival, increase cancer cell death, reduce total HER2 protein levels on the cell surface, and block the Akt signaling pathway more completely.¹⁰ This dual-antibody approach, often combined with a taxane chemotherapy drug, has become a standard regimen for many HER2-positive breast cancer patients.

When the Drug Stops Working

Not every patient responds to trastuzumab, and some who initially respond eventually develop resistance. The most well-studied escape route involves a signaling pathway called PI3K, which operates downstream of HER2. If a cancer cell acquires mutations that keep the PI3K pathway permanently switched on, the cell no longer needs HER2 signaling to survive, making trastuzumab irrelevant regardless of whether it is bound to the receptor.

Two genetic changes drive this resistance most often. One is loss of a tumor-suppressor protein called PTEN, which normally keeps the PI3K pathway in check. The other is activating mutations in the PIK3CA gene. Either change can hyperactivate PI3K signaling on its own. In studies of patients with HER2-positive metastatic breast cancer, activation of the PI3K pathway through PTEN loss or PIK3CA mutation was linked to poorer response to trastuzumab and shorter survival.¹¹ Laboratory experiments corroborated this: introducing a constitutively active version of the PIK3CA gene into trastuzumab-sensitive breast cancer cells rendered them almost completely insensitive to the drug.¹²

This understanding has led to combination strategies pairing trastuzumab with PI3K pathway inhibitors. The goal is to shut down both the front door (HER2 signaling) and the back door (PI3K activation) simultaneously.¹³ Several drugs targeting different nodes in the PI3K pathway have entered clinical trials in this context, though managing the side effects of blocking such a fundamental cellular pathway remains challenging.

The Blood-Brain Barrier Problem

One of the persistent frustrations with trastuzumab is that it struggles to reach brain tumors. The blood-brain barrier, a tightly sealed layer of cells lining the blood vessels that feed the brain, is designed to keep large molecules out of brain tissue. Trastuzumab is a large antibody, and in animal models, only about 3% of an injected dose reaches normal brain tissue, with roughly 5% reaching brain tumors.¹⁴

This is a real clinical issue because HER2-positive breast cancer has a concerning tendency to spread to the brain. Paradoxically, patients on trastuzumab sometimes live long enough for brain metastases to develop in a location the drug cannot effectively patrol. Retrospective analyses suggest that continuing trastuzumab after brain metastases are diagnosed still helps patients live longer, probably because it continues to control cancer elsewhere in the body, and possibly because tumors that have disrupted the blood-brain barrier locally allow some trastuzumab to leak through.¹⁵ Researchers are investigating strategies to temporarily open the barrier, including experimental compounds that enhance trastuzumab delivery to the brain in mouse models.¹⁶ Small-molecule HER2-targeting drugs, which are much smaller than antibodies, are also being used and studied for brain-metastatic disease because they cross the barrier more easily.

HER2-Positive Gastric Cancer

Trastuzumab’s story is often told through breast cancer, but it is not limited to that disease. Roughly one in five advanced gastric or gastroesophageal junction cancers also overexpresses HER2, and the landmark ToGA trial established trastuzumab plus chemotherapy as a standard first-line option for these patients. In that trial, adding trastuzumab extended median overall survival from about 11 months to nearly 14 months, and patients with the highest levels of HER2 expression benefited most, with a median survival of 16 months on the combination.¹⁷ Response rates were also higher with trastuzumab: roughly 47% of patients on the combination had their tumors shrink meaningfully, compared with 35% on chemotherapy alone.¹⁸

The mechanisms at work in gastric cancer are believed to be the same as in breast cancer: immune-mediated killing, inhibition of shedding, reduced receptor signaling, and possible receptor downregulation.¹⁹ However, HER2 testing in gastric cancer has its own quirks. The staining patterns look different from breast cancer under the microscope, and the criteria for calling a tumor HER2-positive had to be adapted for the stomach. This is why HER2 testing protocols and scoring systems are not simply copied from breast cancer to other tumor types.

Cardiac Side Effects and Why They Happen

Heart muscle cells also express HER2, and HER2 signaling plays a role in maintaining heart function and protecting cardiomyocytes from stress. When trastuzumab blocks HER2 on heart cells, it disrupts protective pathways that normally help those cells dispose of damaged internal components. Research has shown that trastuzumab-mediated interference with HER2 signaling in the heart impairs a cellular recycling process called autophagy, leading to a buildup of damaged mitochondria and an increase in harmful reactive oxygen molecules inside heart cells.²⁰

In practice, this means patients on trastuzumab undergo regular heart-function monitoring, typically through echocardiograms every few months. The cardiac effects differ from those caused by traditional chemotherapy drugs like doxorubicin: trastuzumab-related heart dysfunction does not involve the kind of structural damage that anthracyclines cause, and it is usually reversible when the drug is stopped or the dose is adjusted. This distinction matters when oncologists are deciding treatment sequences, especially since some chemotherapy drugs used alongside trastuzumab carry their own cardiac risks.

Antibody-Drug Conjugates Built on Trastuzumab

One of the most significant recent developments in HER2-targeted therapy is the creation of antibody-drug conjugates that use trastuzumab as a delivery vehicle. The idea is to attach a potent chemotherapy payload directly to the antibody, so that when it binds to HER2 and gets pulled inside the cancer cell, the chemo drug is released right where it is needed. Trastuzumab deruxtecan is the most prominent example. It consists of a trastuzumab-based antibody linked to a topoisomerase I inhibitor, and it carries an unusually high ratio of eight drug molecules per antibody, ensuring a strong dose of chemotherapy reaches each target cell.²¹

What makes this approach especially interesting is the bystander effect. Because the released chemotherapy payload can diffuse out of the dying cancer cell and into neighboring cells, trastuzumab deruxtecan can kill nearby tumor cells even if those neighbors express relatively low levels of HER2. This has expanded the drug’s usefulness to cancers previously classified as “HER2-low,” a category that did not even exist as a treatment target before antibody-drug conjugates arrived.

Resistance to these newer conjugates follows different patterns than resistance to trastuzumab itself. For example, some tumors upregulate drug efflux pumps, molecular machinery that actively pumps the chemotherapy payload back out of the cell before it can do damage. High expression of one such pump, ABCC1, has been linked to shorter survival in patients treated with trastuzumab deruxtecan.²² This is a fundamentally different resistance mechanism from the PI3K pathway alterations that defeat plain trastuzumab, because the tumor is not escaping the antibody’s targeting but rather neutralizing the toxic cargo it carries.

How Patients Are Selected for Trastuzumab

Not every breast or gastric cancer gets trastuzumab. The drug only works if the tumor has enough HER2 to target, and determining that requires specific testing on a biopsy sample. Two main methods are used. Immunohistochemistry stains the tissue and scores how much HER2 protein is present on the cell surface, on a scale from 0 to 3+. A score of 3+ means strongly HER2-positive and qualifies for treatment. A score of 2+ is ambiguous and triggers a second test.

That second test is fluorescence in situ hybridization, which counts the actual number of HER2 gene copies in the tumor cells. Current guidelines classify tumors into groups based on both the ratio of HER2 gene copies to a reference chromosome and the average number of HER2 copies per cell.²³ The testing criteria have been refined multiple times over the years, and borderline cases remain one of the trickier areas in pathology. Getting the HER2 call right is critical: give trastuzumab to a patient whose tumor is not truly driven by HER2, and you add side effects without benefit. Miss a genuinely HER2-positive tumor, and you withhold one of the most effective targeted therapies in oncology.

This testing complexity also explains why researchers continue to study receptor crosslinking and internalization. When trastuzumab binds and promotes the uptake of HER2 into the cell’s interior for degradation, it can pull the related receptor HER3 down with it while leaving EGFR, a different family member, on the surface.²⁴ Understanding exactly which receptors get pulled down and through which cellular pathways feeds back into designing better drugs and better testing criteria, because the biology of HER2 keeps turning out to be more nuanced than the simple story of “too many receptors, block them” that oncology textbooks once told.